 - Patients in the Extension cohorts melanoma or adenocarcinoma of the colon or rectum must have both a V600E BRAF mutation and measurable disease by RECIST V 1.0 criteria prior to the administration of PLX4032. All patients enrolled must provide archival or fresh melanoma tumor biopsy for confirmation of V600E BRAF mutation status by TaqMan assay 